{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:49:00Z","timestamp":1790113740934,"version":"4.0.1"},"reference-count":16,"publisher":"Siapec Servizi Srl","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologica"],"DOI":"10.32074\/1591-951x-937","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T08:53:24Z","timestamp":1710406404000},"page":"55-61","source":"Crossref","is-referenced-by-count":14,"title":["TROP-2, NECTIN-4 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma"],"prefix":"10.32074","volume":"116","author":[{"given":"Matteo","family":"Brunelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Gobbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Malpeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Sirgiovanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Caserta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Munari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Francesconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cali\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Martignoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Cimadamore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Veccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pierconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle Malak","family":"Hattab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albino","family":"Eccher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ascani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Buffoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bracarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"21774","published-online":{"date-parts":[[2024,2]]},"reference":[{"key":"10.32074\/1591-951X-937_ref1","doi-asserted-by":"crossref","unstructured":"Mollica V, Rizzo A, Montironi R, et al. Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. Cancers. 2020;12:1449. https:\/\/doi.org\/10.3390\/cancers12061449","DOI":"10.3390\/cancers12061449"},{"key":"10.32074\/1591-951X-937_ref2","doi-asserted-by":"crossref","unstructured":"Chou J, Trepka K, Sj\u00f6str\u00f6m M, et al. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. Eur Urol Oncol. 2022;5:714-718. https:\/\/doi.org\/10.1016\/j.euo.2021.11.005","DOI":"10.1016\/j.euo.2021.11.005"},{"key":"10.32074\/1591-951X-937_ref3","doi-asserted-by":"crossref","unstructured":"Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39:2474-2485. https:\/\/doi.org\/10.1200\/JCO.20.03489","DOI":"10.1200\/JCO.20.03489"},{"key":"10.32074\/1591-951X-937_ref4","doi-asserted-by":"crossref","unstructured":"Kl\u00fcmper N, Ralser DJ, Ellinger J, et al. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. Clin Cancer Res Off J Am Assoc Cancer Res. 2023;29:1496-1505. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1764","DOI":"10.1158\/1078-0432.CCR-22-1764"},{"key":"10.32074\/1591-951X-937_ref5","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell PH, Milowsky MI, Petrylak DP, et al. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2023;JCO2202887. https:\/\/doi.org\/10.1200\/JCO.22.02887","DOI":"10.1200\/JCO.22.02887"},{"key":"10.32074\/1591-951X-937_ref6","doi-asserted-by":"crossref","unstructured":"Hoffman-Censits JH, Lombardo KA, Parimi V, et al. Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes. Appl Immunohistochem Mol Morphol. 2021;29:619-625. https:\/\/doi.org\/10.1097\/PAI.0000000000000938","DOI":"10.1097\/PAI.0000000000000938"},{"key":"10.32074\/1591-951X-937_ref7","doi-asserted-by":"crossref","unstructured":"Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401-404. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095","DOI":"10.1158\/2159-8290.CD-12-0095"},{"key":"10.32074\/1591-951X-937_ref8","doi-asserted-by":"crossref","unstructured":"Xie Z, Bailey A, Kuleshov MV, et al. Gene Set Knowledge Discovery with Enrichr. Curr Protoc 2021;1:e90. https:\/\/doi.org\/10.1002\/cpz1.90","DOI":"10.1002\/cpz1.90"},{"key":"10.32074\/1591-951X-937_ref9","doi-asserted-by":"crossref","unstructured":"Challita-Eid PM, Satpayev D, Yang P, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res. 2016;76:3003-3013. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1313","DOI":"10.1158\/0008-5472.CAN-15-1313"},{"key":"10.32074\/1591-951X-937_ref10","doi-asserted-by":"crossref","unstructured":"Sanguedolce F, Zanelli M, Palicelli A, et al. HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role. Int J Mol Sci. 2023;24:3720. https:\/\/doi.org\/10.3390\/ijms24043720","DOI":"10.3390\/ijms24043720"},{"key":"10.32074\/1591-951X-937_ref11","doi-asserted-by":"crossref","unstructured":"Zajac M, Scott M, Ratcliffe M, et al. Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma. Diagn Pathol. 2019;14:99. https:\/\/doi.org\/10.1186\/s13000-019-0873-6","DOI":"10.1186\/s13000-019-0873-6"},{"key":"10.32074\/1591-951X-937_ref12","doi-asserted-by":"crossref","unstructured":"Naik M, Rao BV, Challa S, et al. Utility of GATA-3 and associated immunohistochemical markers in the differential diagnosis of poorly differentiated urothelial carcinoma. J Cancer Res Ther. 2023;19:S0. https:\/\/doi.org\/10.4103\/jcrt.jcrt_1039_21","DOI":"10.4103\/jcrt.jcrt_1039_21"},{"key":"10.32074\/1591-951X-937_ref13","doi-asserted-by":"crossref","unstructured":"Leivo MZ, Elson PJ, Tacha DE, et al. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma. Pathology. 2016;48:543-549. https:\/\/doi.org\/10.1016\/j.pathol.2016.05.008","DOI":"10.1016\/j.pathol.2016.05.008"},{"key":"10.32074\/1591-951X-937_ref14","doi-asserted-by":"crossref","unstructured":"Zhu F, Qian W, Zhang H, et al. SOX2 Is a Marker for Stem-like Tumor Cells in Bladder Cancer. Stem Cell Rep. 2017;9:429-437. https:\/\/doi.org\/10.1016\/j.stemcr.2017.07.004","DOI":"10.1016\/j.stemcr.2017.07.004"},{"key":"10.32074\/1591-951X-937_ref15","doi-asserted-by":"crossref","unstructured":"Ooki A, Begum A, Marchionni L, et al. Arsenic promotes the COX2\/PGE2-SOX2 axis to increase the malignant stemness properties of urothelial cells. Int J Cancer. 2018;143:113-126. https:\/\/doi.org\/10.1002\/ijc.31290","DOI":"10.1002\/ijc.31290"},{"key":"10.32074\/1591-951X-937_ref16","doi-asserted-by":"crossref","unstructured":"Plage H, Samtleben H, Hofbauer S, et al. GATA3 expression loss is linked to stage progression but is unrelated to prognosis in muscle-invasive urothelial carcinoma of the bladder. Hum Pathol. 2022;130:10-17. https:\/\/doi.org\/10.1016\/j.humpath.2022.09.004","DOI":"10.1016\/j.humpath.2022.09.004"}],"container-title":["Pathologica"],"original-title":[],"link":[{"URL":"https:\/\/www.pathologica.it\/article\/view\/937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:27:53Z","timestamp":1730813273000},"score":1,"resource":{"primary":{"URL":"https:\/\/old.pathologica.it\/article\/view\/937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.32074\/1591-951x-937","relation":{},"ISSN":["1591-951X"],"issn-type":[{"value":"1591-951X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"article-number":"6"}}